Well, Well, Well.
The recently completed phase 2 trial (NCT03522298) enrolled patients with newly diagnosed GBM with unmethylated MGMT promoter status following surgical resection and chemotherapy
Dr Wen and Dr De Groot were encouraged with Kazia's paxalisib phase 2 final trial results, enough to present an abstract and discuss the results at the upcoming ESMO Congress 2022, They also they joined the Kazia Scientific Advisory Board (SAB).
Dr Wen and Dr De Groot should have enough influence and clout to guide the GBM AGILE investigators who are continuously analyzing the data from the paxalisib study arm, especially for the data results relating to the enrolled patients with newly diagnosed GBM with unmethylated MGMT promoter status.
Regards.
- Forums
- ASX - By Stock
- GBM PAXALISIB ESMO 09/09/2022
Well, Well, Well.The recently completed phase 2 trial...
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add KZA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
1CG
ONE CLICK GROUP LIMITED
Mark Waller, MD
Mark Waller
MD
Previous Video
Next Video
SPONSORED BY The Market Online